Zepbound Archives

Sleep Apnea is a common disorder with severe potential health implications. Its link with obesity is well-documented and the search for effective treatments is continuous. One promising candidate is Zepbound, a weight loss drug developed by Eli Lilly. Sleep apnea is a severe sleep disorder that occurs when a person's breathing repeatedly stops and starts during sleep. There are two main types: obstructive sleep apnea, the more prevalent form, and central sleep apnea. It's a potentially severe disorder with symptoms like gasping for air during sleep, snoring loudly, and waking up feeling tired. Obesity is a significant risk factor for sleep apnea. About 70% of people with obstructive sleep apnea are overweight or obese. The excess fat deposits around the upper airway obstruct breathin...

New obesity drugs are showing promising results in helping some people lose weight, but the injections remain out of reach for millions of older Americans because Medicare is prohibited from covering such drugs. A broad and growing bipartisan coalition of drugmakers and lawmakers is gearing up to push for change next year. As obesity rates rise among older adults, some lawmakers say the United States cannot afford to maintain a decades-old law that prevents Medicare from paying for new weight-loss drugs, including Wegovy and Zepbound. Prevents from doing. But research shows that the upfront cost of covering those drugs is so high that it could deplete Medicare's already shaky bank account. The Food and Drug Administration has in recent years approved a new class of weekly injections ...

Tag: Zepbound

Eli Lilly’s Zepbound for Weight Loss Shows Promise in Sleep Apnea Treatment

Medicare Introduce New Weight Loss Drug Including Wegovy and Zepbound